Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Midas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA CHMP Recommends Grant of Marketing Authorization of Ranibizumab Biosimilar","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"},{"orgOrder":0,"company":"Midas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ranibizumab Launch - Midas Pharma is the Marketing Authorisation Holder (MAH) of a Biosimilar","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Midas Pharma","sponsor":"Pharmacare Premium","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Midas Pharma\u2019s Partner, the Malta-based Generics Developer Pharmacare Premium, Has Successfully Conducted BE-Studies for Both Strengths of a Generic Version of Norvatis\u2019 Vorient\u00ae.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Midas Pharma","sponsor":"Apontis Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Apontis Pharma and Midas Pharma Agree on Further Development Partnership for The Market Launch of A Single Pill with Pan-European Intellectual Property Rights","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Midas Pharma","sponsor":"Apontis Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"APONTIS PHARMA and Midas Pharma Announce Development Partnership to Launch Single Pill with Pan-european Intellectual Property Rights","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Midas Pharma","sponsor":"Coripharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Coripharma and Midas Have Entered into an Exclusive Licensing Partnership","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by Midas Pharma

    Menu

    Midas Pharma

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    Key Products KEY PRODUCTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Midas Pharma

              Contact Supplier
              • Development Update
              Virtual BoothMidas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.
              Contact Supplier Contact Supplier
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Ranibizumab Launch - Midas Pharma is the Marketing Authorisation Holder (MAH) of a Biosimilar

              Details:

              Ranivisio (ranibizumab) is a VEGF-A inhibitor, which is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, and diabetic macular edema.

              Lead Product(s): Ranibizumab

              Therapeutic Area: Ophthalmology Product Name: Ranivisio

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 11, 2023

              Midas Pharma

              API China 2024

              Attending

              envelop Contact Supplier

              Midas Pharma

              Contact Supplier
              • Deals
              Virtual BoothMidas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.
              Contact Supplier Contact Supplier
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Apontis Pharma and Midas Pharma Agree on Further Development Partnership for The Market Launch of A Single Pill with Pan-European Intellectual Property Rights

              Details:

              The aim of the partnership is the contract development of a Single Pill, Biramlo, with a combination of two leading active ingredients,bisoprolol fumarate and amlodipine for the treatment of high blood pressure (hypertension).

              Lead Product(s): Bisoprolol Fumarate,Amlodipine

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Biramlo

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Apontis Pharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership July 19, 2022

              Midas Pharma

              API China 2024

              Attending

              envelop Contact Supplier

              Midas Pharma

              Contact Supplier
              • Development Update
              Virtual BoothMidas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.
              Contact Supplier Contact Supplier
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              EMA CHMP Recommends Grant of Marketing Authorization of Ranibizumab Biosimilar

              Details:

              The active substance of Ranivisio is ranibizumab, a monoclonal antibody fragment (ATC code: S01LA04) which modulates angiogenesis by inhibiting vascular endothelial growth factor A. Ranivisio is a biosimilar medicinal product.

              Lead Product(s): Ranibizumab

              Therapeutic Area: Ophthalmology Product Name: Ranivisio

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 23, 2022

              Midas Pharma

              API China 2024

              Attending

              envelop Contact Supplier

              Midas Pharma

              Contact Supplier
              • Deals
              Virtual BoothMidas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.
              Contact Supplier Contact Supplier
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              APONTIS PHARMA and Midas Pharma Announce Development Partnership to Launch Single Pill with Pan-european Intellectual Property Rights

              Details:

              The objective is the contract development of a Single Pill with a combination of three leading active ingredients, including candesartan cilexetil, amlodipine besylate and atorvastatin calcium trihydrate for the treatment of high blood pressure (hypertension).

              Lead Product(s): Candesartan Cilexetil,Amlodipine Besylate,Atorvastatin

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Small molecule

              Recipient: Apontis Pharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership December 14, 2021

              Midas Pharma

              API China 2024

              Attending

              envelop Contact Supplier

              Midas Pharma

              Contact Supplier
              • Development Update
              Virtual BoothMidas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.
              Contact Supplier Contact Supplier
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Midas Pharma’s Partner, the Malta-based Generics Developer Pharmacare Premium, Has Successfully Conducted BE-Studies for Both Strengths of a Generic Version of Norvatisâ€...

              Details:

              Vorient-Generic (pazopanib) is a kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma & advanced soft tissue sarcoma who have received prior chemotherapy.

              Lead Product(s): Pazopanib Hydrochloride

              Therapeutic Area: Oncology Product Name: Vorient-Generic

              Highest Development Status: Phase III Product Type: Small molecule

              Recipient: Pharmacare Premium

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 26, 2021

              Midas Pharma

              API China 2024

              Attending

              envelop Contact Supplier

              Midas Pharma

              Contact Supplier
              • Deals
              Virtual BoothMidas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.
              Contact Supplier Contact Supplier
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Coripharma and Midas Have Entered into an Exclusive Licensing Partnership

              Details:

              Corifarma and Midas entered into an exclusive out-licensing cooperation for the European territory. The respective product, Raltegravir, can be launched in the EU in 2023 as a generic and is used in treatment of HIV/AIDS.

              Lead Product(s): Raltegravir Potassium

              Therapeutic Area: Infections and Infectious Diseases Product Name: Raltegravir-Generic

              Highest Development Status: Phase III Product Type: Small molecule

              Recipient: Coripharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement September 23, 2020

              Midas Pharma

              API China 2024

              Attending

              envelop Contact Supplier

              Midas Pharma
              Send me more info on How To Grow My Business Digitally?
              Post Enquiry
              POST ENQUIRY